FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma

• Main Authors: Junsheng Li, Qian Zhang, Peicong Ge, Chaofan Zeng, Fa Lin, Wen Wang, Jizong Zhao
• Format: Article
• Language: English
• Published: Hindawi Limited 2020-01-01
• Series: Disease Markers
• Online Access: http://dx.doi.org/10.1155/2020/8888085
• ISSN: 0278-0240; 1875-8630

Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. Methods. We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. Results. We found that FAM225B was upregulated in rGBMs (P=0.0009). The expression of FAM225B increased with the grades of gliomas (P<0.0001). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group (P=0.0041). Similar result was found in the training set (P=0.0340) and verified in the validation set (P=0.0292). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs (P=0.003). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. Conclusions. FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs.